Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.
Sarilumab can reverse IL-6 enhanced colony formation in HCC cells under sorafenib or regorafenib treatment.[1]
Sarilumab has been shown in preclinical studies to inhibit IL-6 signalling in a dose-dependent manner[2].
[1] Dai Z, et al. Cancer Lett. 2022 Jan 1;524:161-171. [2] Huizinga TW, et al. Ann Rheum Dis. 2014, 73(9):1626-34.